Literature DB >> 17931150

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.

Stanley L Hem1, Harm Hogenesch.   

Abstract

Aluminum-containing adjuvants are an important component of many vaccines because they safely potentiate the immune response. The structure and properties of aluminum hydroxide adjuvant, aluminum phosphate adjuvant and alum-precipitated adjuvants are presented in this review. The major antigen adsorption mechanisms, electrostatic attraction and ligand exchange, are related to the adjuvant structure. The manner by which aluminum-containing adjuvants potentiate the immune response is related to the structure, properties of the adjuvant and adsorption mechanism. Immunopotentiation occurs through the following sequential steps: inflammation and recruitment of antigen-presenting cells, retention of antigen at the injection site, uptake of antigen, dendritic cell maturation, T-cell activation and T-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931150     DOI: 10.1586/14760584.6.5.685

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  72 in total

Review 1.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 2.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

Review 3.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

5.  Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

Authors:  Wendy A Keitel; James D Campbell; John J Treanor; Emmanuel B Walter; Shital M Patel; Fenhua He; Diana L Noah; Heather Hill
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

6.  Biocompatible inorganic nanoparticles for [18F]-fluoride binding with applications in PET imaging.

Authors:  Maite Jauregui-Osoro; Peter A Williamson; Arnaud Glaria; Kavitha Sunassee; Putthiporn Charoenphun; Mark A Green; Gregory E D Mullen; Philip J Blower
Journal:  Dalton Trans       Date:  2011-03-11       Impact factor: 4.390

7.  Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis.

Authors:  Lucian Visan; Violette Sanchez; Margaux Kania; Aymeric de Montfort; Luis M de la Maza; Salvador Fernando Ausar
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 8.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

9.  Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Authors:  Daniel F Hoft; Kathleen Lottenbach; Johannes B Goll; Heather Hill; Patricia L Winokur; Shital M Patel; Rebecca C Brady; Wilbur H Chen; Kathryn Edwards; C Buddy Creech; Sharon E Frey; Tamara P Blevins; Rachelle Salomon; Robert B Belshe
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

10.  Comparison of adjuvant and adjuvant-free murine experimental asthma models.

Authors:  M L Conrad; A O Yildirim; S S Sonar; A Kiliç; S Sudowe; M Lunow; R Teich; H Renz; H Garn
Journal:  Clin Exp Allergy       Date:  2009-05-03       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.